MedTrace Logo

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

NCT06494943 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-02-25

No results posted yet for this study

Summary

This study aims to investigate the efficacy and safety of combining sintilimab and the TP regimen with/without IBI110 for neoadjuvant chemotherapy in resectable locally advanced head and neck squamous cell carcinoma (HNSCC).

Conditions

Interventions

DRUG

Sintilimab

PD-1 inhibitor

DRUG

IBI110

LAG-3 inhibitor

DRUG

Paclitaxel

Chemotherapy

DRUG

Cis Platinum

Chemotherapy

PROCEDURE

Surgery

Definitive surgery

RADIATION

Adjuvant radiation

Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-26
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06494943 on ClinicalTrials.gov